CPX-351 Therapy for MDS After Hypomethylating Agent Failure
A Phase II Study of CPX-351 as a Novel Therapeutic Approach for Patients With Myelodysplastic Syndromes (MDS) After Hypomethylating Agent Failure
Sponsor: Case Comprehensive Cancer Center
Terminated
Slow Accrual
Other terminated trials from Case Comprehensive Cancer Center
Other Myelodysplastic Syndrome (MDS) trials with similar outcome
This PHASE2 trial investigates Myelodysplastic Syndrome (MDS) and is currently terminated or withdrawn. Case Comprehensive Cancer Center leads this study, which shows 10 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
May 2021 — May 2022 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Feb 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Aug 2019 — Aug 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2019 — Aug 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Case Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .